Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly

Journal of Medical Virology

Volumn 61, Issue 1, 2000, Pages 94-99

  De Jong, Jan C ^a   Beyer, Walter E P ^a   Palache, Abraham M ^b   Rimmelzwaan, Guus F ^a   Osterhaus, Albert D M E ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Cross reactivity; Efficacy; Influenza; Mismatch; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; FERRET; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA VACCINATION; INFLUENZA VIRUS; NONHUMAN; VIRUS STRAIN;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODY FORMATION; FERRETS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; VACCINATION;

INFLUENZA A VIRUS; INFLUENZA VIRUS; MUSTELA PUTORIUS FURO; RNA VIRUSES;

EID: 0034072605     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(200005)61:1<94::AID-JMV15>3.0.CO;2-C     Document Type: Article

References (10)

1. Anonymous. 1986. Recommended composition of influenza vaccines for use in the 1986/87 season: an update. Wkly Epidemiol Rec 61:237-244.
2. Anonymous. 1998. Recommended composition of influenza virus vaccines for use in the 1998-1999 season. Wkly Epidemiol Rec 73:56-61.
3. Arden NH, Patriarca PA, Lui KJ, Harmon MW, Brandon F, Kendal AP. 1986. Safety and immunogenicity of a 45 μg supplemental dose of inactivated split-virus influenza B vaccine in the elderly. J Infect Dis 153:805-806.
4. Betts RF. 1995. Influenza virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone. p 1546-1567.
5. Beyer WEP, Palache AM, Baljet M, Masurel N. 1989. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 7:385-394.
6. Masurel N, Ophof P, de Jong P. 1981. Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersev/76 (H1N1) virus. J Hyg (Camb) 87:201-209.
7. McElhaney JE, Meneilly GS, Lechelt KE, Beattie BL, Bleackley RC. 1993. Antibody response to whole-virus and split-virus influenza vaccines in successful ageing. Vaccine 11:1055-1060.
8. Mullooly J, Bennett M, Hornbrook M, Williams W, Patriarca P, Rhodes P. 1993. Cost-effectiveness of influenza vaccination programs in an HMO: the experience of Kaiser Permanente, Northwest Region. In: Hannoun C, Kendal AP, Klenk HD, Ruben FL, editors. Options for the Control of Influenza II. Proceedings of the International Conference on Options for the Control of Influenza, Courchevel, 27 September to 2 October 1992. Amsterdam: Elsevier Science Publishers, p 53-62.
9. Powers DC, Belshe RB. 1994. Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin." J Infect Dis 169:1125-1129.
10. Prins CJM. 1998. Many deaths in March and April 1998. Monthly Bulletin of Population Statistics (Maandstatistiek van de Bevolking, CBS) 46:8-9. [Dutch article with English summary].